Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

2013; American Psychiatric Association; Volume: 170; Issue: 10 Linguagem: Inglês

10.1176/appi.ajp.2013.13030392

ISSN

1535-7228

Autores

James W. Murrough, Dan V. Iosifescu, Lee C. Chang, Rayan K. Al Jurdi, Charles E. Green, Andrew M. Perez, Syed Iqbal, Sarah Pillemer, Alexandra L. Foulkes, Asim A. Shah, Dennis S. Charney, Sanjay J. Mathew,

Tópico(s)

Neuroscience and Neuropharmacology Research

Resumo

Intravenous ketamine demonstrated rapid antidepressant effects in an optimized study design, improving depression severity in 64% of treatment-resistant patients 24 hours after a single dose. The double-blind trial provides evidence for the role of the N-methyl-d-aspartate glutamate receptor in depression, a receptor not currently activated by existing antidepressant drugs.

Referência(s)